PharmAla Biotech Holdings Inc. filed Amendment No. 1 to a Schedule 13G with the SEC on October 21, 2026, disclosing beneficial ownership of 132,867 shares of Jupiter Neurosciences, Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting person: PharmAla Biotech Holdings Inc., incorporated in Ontario, Canada, filed as a corporation (type CO).
  • Shares beneficially owned: 132,867 shares of Jupiter Neurosciences common stock, par value $0.0001 per share.
  • Percent of class: 10.1%, based on 1,318,521 outstanding shares of the issuer as of September 21, 2026.
  • Voting and dispositive power: Sole voting power and sole dispositive power each covering 132,867 shares; shared voting and shared dispositive power each reported as 0.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Certification: The filing certifies the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

PharmAla Biotech's Amended Ownership Disclosure in Jupiter Neurosciences

According to the filing, PharmAla Biotech Holdings Inc., headquartered at 1 Adelaide Street E., Suite 801, Toronto, Ontario, Canada, submitted Amendment No. 1 to its Schedule 13G relating to its holdings in Jupiter Neurosciences, Inc. (NASDAQ:JUNS). Jupiter Neurosciences is listed with its principal executive offices at 1001 North US Hwy 1, Suite 504, Jupiter, FL 33477. The securities at issue are shares of common stock with CUSIP number 48208B203.

The filing reports that PharmAla Biotech beneficially owns 132,867 shares, representing 10.1% of the class. That percentage was calculated based on 1,318,521 outstanding issuer shares as of September 21, 2026, as noted in the filing. PharmAla Biotech holds sole voting power and sole dispositive power over all 132,867 shares, with no shared voting or dispositive power reported.

The filing was signed by William Avery, Chief Financial Officer of PharmAla Biotech Holdings Inc., on October 21, 2026. The certification included in the filing states that, to the best of the signer's knowledge and belief, the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."

What Was Disclosed

PharmAla Biotech Holdings Inc. disclosed in this amended Schedule 13G that it beneficially owns 132,867 shares of Jupiter Neurosciences common stock, equal to 10.1% of the class, as of the September 30, 2026 triggering date, with all voting and dispositive power held solely.